Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Filing Details

Accession Number:
0001225208-17-010828
Form Type:
4
Zero Holdings:
No
Publication Time:
2017-06-02 18:17:36
Reporting Period:
2017-05-31
Filing Date:
2017-06-02
Accepted Time:
2017-06-02 18:17:36
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1269021 Portola Pharmaceuticals Inc PTLA () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1250409 W Jeffrey Bird 755 Page Mill Road, Suite A-200
Palo Alto CA 94304-1005
Yes No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2017-06-01 8,800 $31.85 45,402 No 4 P Indirect By Ltd Partnership (NEST)
Common Stock Disposition 2017-05-31 147,523 $0.00 810,968 No 4 J Indirect By Ltd Partnership (SHV)
Common Stock Acquisiton 2017-06-01 110,642 $31.85 921,610 No 4 P Indirect By Ltd Partnership (SHV)
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 P Indirect By Ltd Partnership (NEST)
No 4 J Indirect By Ltd Partnership (SHV)
No 4 P Indirect By Ltd Partnership (SHV)
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 3,000 Direct
Common Stock 59,053 Indirect By Trust (Trustees)
Footnotes
  1. In connection with the Liquidation, the reporting person entered into an agreement with the Limited Partner to repurchase 8,800 Distributed Common Shares from the Limited Partner at a purchase price equal to the average of the mean between the closing bid and ask prices over the ninety (90)-day period ended March 31, 2017.
  2. Shares held by a limited partnership of which the reporting person is a trustee of a trust which is the General Partner. The reporting person disclaims beneficial ownership of these shares except as to the reporting person's pecuniary interest therein.
  3. On May 31, 2017, a limited partner (the "Limited Partner") of Sutter Hill Ventures, a California Limited Partnership ("SHV") liquidated its interest in SHV in return for its ratable share of the holdings of SHV, resulting in SHV's disposition to the Limited Partner of 147,523 shares (the "Distributed Common Shares") of the Issuer's common stock (the "Liquidation").
  4. Shares held by SHV. The reporting person is a managing director and member of the management committee of the general partner of SHV. The reporting person disclaims beneficial ownership in these shares except as to the reporting person's pecuniary interest therein.
  5. In connection with the Liquidation, SHV entered into an agreement with the Limited Partner to repurchase 110,642 Distributed Common Shares from the Limited Partner at a purchase price equal to the average of the mean between the closing bid and ask prices over the ninety (90)-day period ended March 31, 2017.
  6. Shares held by a trust of which the reporting person is a trustee. The reporting person disclaims beneficial ownership in these shares except as to the reporting person's pecuniary interest therein.